Rybrevant Faspro

NDC product · U.S. Food and Drug Administration (openFDA) · United States

  • Product NDC 57894-514
  • Package NDC 57894-514-01
  • Application number BLA761433
  • SPL ID 71fc1711-5a9a-48bf-9d1b-b33be9b76d64
  • SPL set ID 9e58b045-e352-4f62-99bf-77fae1bebc69
  • UNII 0JSR7Z0NB6
  • UNII 743QUY4VD8
  • RxCUI 2729297
  • RxCUI 2729304
  • RxCUI 2729306
  • RxCUI 2729307
  • RxCUI 2735796
  • RxCUI 2735797
  • RxCUI 2735803
  • RxCUI 2735804

What the source publishes

Labeler
Janssen Biotech, Inc.
Active ingredients
AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT)
Form
INJECTION
Routes
SUBCUTANEOUS
Administrative status
present-in-source-snapshot
Marketing status
BLA
Product type
HUMAN PRESCRIPTION DRUG
Prescription
Prescription or restricted

Names this record is found by

Complete source data
us:fda:ndc:57894-514_71fc1711-5a9a-48bf-9d1b-b33be9b76d64
{
  "name": "Rybrevant Faspro",
  "splId": "71fc1711-5a9a-48bf-9d1b-b33be9b76d64",
  "labels": [
    {
      "setId": "9e58b045-e352-4f62-99bf-77fae1bebc69",
      "labelUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e58b045-e352-4f62-99bf-77fae1bebc69",
      "labelPdfUrl": "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=9e58b045-e352-4f62-99bf-77fae1bebc69"
    }
  ],
  "routes": [
    "SUBCUTANEOUS"
  ],
  "labeler": "Janssen Biotech, Inc.",
  "finished": true,
  "packaging": [
    {
      "sample": false,
      "description": "1 VIAL, SINGLE-DOSE in 1 CARTON (57894-514-01)  / 14 mL in 1 VIAL, SINGLE-DOSE",
      "package_ndc": "57894-514-01",
      "identifierStatus": "well-formed",
      "marketing_start_date": "20251219"
    }
  ],
  "productId": "57894-514_71fc1711-5a9a-48bf-9d1b-b33be9b76d64",
  "useDomain": "unknown",
  "dosageForm": "INJECTION",
  "productNdc": "57894-514",
  "deaSchedule": null,
  "genericName": "AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT)",
  "productType": "HUMAN PRESCRIPTION DRUG",
  "listingStatus": "present-in-source-snapshot",
  "targetSpecies": [],
  "approvalStatus": "not-established-by-ndc-listing",
  "labelAssociation": "openFDA-harmonized-set-ids; not a product-level approval match",
  "marketingEndDate": null,
  "activeIngredients": [
    {
      "name": "AMIVANTAMAB",
      "strength": "2240 mg/14mL"
    },
    {
      "name": "HYALURONIDASE (HUMAN RECOMBINANT)",
      "strength": "28000 mg/14mL"
    }
  ],
  "applicationNumber": "BLA761433",
  "marketingCategory": "BLA",
  "stateRestrictions": {
    "status": "not-collected",
    "observations": []
  },
  "useDomainEvidence": {
    "basis": "unreviewed",
    "field": null,
    "value": null,
    "version": 1,
    "sourceId": "us.fda.ndc"
  },
  "marketingStartDate": "20251219",
  "targetSpeciesStatus": "not-reported",
  "prescriptionCategory": "prescription-or-restricted",
  "harmonizedIdentifiers": {
    "nui": [
      "N0000175531",
      "M0009499"
    ],
    "upc": [
      "0357894522010"
    ],
    "unii": [
      "0JSR7Z0NB6",
      "743QUY4VD8"
    ],
    "rxcui": [
      "2729297",
      "2729304",
      "2729306",
      "2729307",
      "2735796",
      "2735797",
      "2735803",
      "2735804"
    ],
    "spl_set_id": [
      "9e58b045-e352-4f62-99bf-77fae1bebc69"
    ],
    "pharm_class_cs": [
      "Glycoside Hydrolases [CS]"
    ],
    "pharm_class_epc": [
      "Endoglycosidase [EPC]"
    ],
    "manufacturer_name": [
      "Janssen Biotech, Inc."
    ],
    "is_original_packager": [
      true
    ]
  },
  "listingExpirationDate": "20271231"
}

Read this record from your own software

The same record, with every field and its provenance, is one request away. An API key is free and works immediately.

GET /v1/drugs/record
curl -G "https://api.medifontis.com/v1/drugs/record" \
  -H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
  --data-urlencode "country=us" \
  --data-urlencode "sourceId=us.fda.ndc" \
  --data-urlencode "id=us:fda:ndc:57894-514_71fc1711-5a9a-48bf-9d1b-b33be9b76d64"